TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00784862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1mg, orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1mg, orally, once daily
Study: NCT03296540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel (Crushed tablets)
Description: loading dose of 6 crushed tablets 10mg Prasugrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel (Integral tablets)
Description: loading dose of 6 integral tablets of 10mg Prasugrel
Study: NCT00784862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20mg, orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20mg, orally, once daily
Study: NCT00997789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamide
Description: Rebamipide 100 mg Tablet, three times a day
Study: NCT04904367

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep tissue massage
Description: The amount of pressure during the massage was adjusted by the physiotherapist with reference to muscle tissue palpation in the patients. During the massage, olecranon, pisiform bone protrusion, metacarpophalangeal and proximal interphalangeal joint faces forearm, wrist and fingers were used during the massage to reach deep tissue. As a massage technique, compression and stretching techniques are used in combination.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: For 4 weeks 20 session, this group were applied hot pack with 20 minutes of conventional TENS to back and neck region, followed by 4 minutes of ultrasound at a frequency of 3 MHz and at a dosage of 1 w / cm2.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: For 4 weeks 20 session, this group were applied hot pack with 20 minutes of conventional TENS to back and neck region, followed by 4 minutes of ultrasound at a frequency of 3 MHz and at a dosage of 1 w / cm2.
Study: NCT02843412

Intervention type: PROCEDURE
Intervention: choose two tumor tissue paraffin blocks
Study: NCT03765125

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: collagen peptide test
Description: Collagen peptides from bovine skin with an average molecular weight of approx. 2,000 g/mol. Average particle size is about 150 μm.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: collagen peptide placebo
Description: collagen peptide placebo
Study: NCT04419467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL346
Description: VEGF-B antagonist monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL346
Description: VEGF-B antagonist monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT02563145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-time fMRI feedback
Description: feedback about activation patterns in brain regions related with instrumental aggression

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Psychoeducation, general counselling
Study: NCT02448966

Intervention type: PROCEDURE
Intervention: open esophagectomy
Study: NCT02557854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin HCl liposomal injection
Description: 50mg IV every 4 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips Sonalleve MR-HIFU Hyperthermia
Description: Hyperthermia to 42C for 30 minutes every 4 weeks
Study: NCT02733406

Intervention type: OTHER
Group type: OTHER
Intervention: Target Controlled Infusion

Intervention type: OTHER
Group type: OTHER
Intervention: Velocity Controlled Infusion
Study: NCT01396902

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: You will receive an immunization handout and verbal instructions regarding your child's next apt. Your child's immuniztion records will also be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: You will receive text message reminders prior to your child's two, four and six month immunization due dates. You will be asked to take part in a phone interview and your child's immuniztion records will be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
Study: NCT01151540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rufinamide
Description: The target dosage is approximately 45 mg/kg/day, taken orally twice a day.
Study: NCT02448966

Intervention type: PROCEDURE
Intervention: Minimally invasive esophagectomy
Study: NCT01344798

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV1-gamma-sarcoglycan vector injection
Description: single intramuscular injection into carpi radialis muscle under open procedure
Study: NCT02905903

Intervention type: DRUG
Group type: OTHER
Intervention: Tricholoacetic Acid (TCA)
Description: We will be applying 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study.
Study: NCT01176370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Pulse™ (Implantable Counterpulsation Therapy)
Description: C-Pulse System is an implantable, non-blood contacting, non-obligatory, heart assist device.
Study: NCT04413721

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RBC transfustion
Description: When the hemoglobin concentration fell below 7.0 g per deciliter, RBC were given to maintain the hemoglobin concentrations in the range of 7.0 to 10.0g /dL

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RBC transfustion
Description: When the hemoglobin concentration fell below 7.0 g per deciliter, RBC were given to maintain the hemoglobin concentrations in the range of 7.0 to 10.0g /dL
Study: NCT02982486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg every 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Ninolumab 240 mg IV every 2 weeks
Study: NCT02705118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic Imaging fusion of ultrasonography and MRI
Description: Radiofrequency ablation for hepatic malignancies will be performed with automatic registration registration. Except the imaging registration, all other procedures for RF ablation is same.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Imaging fusion of ultrasonography and MRI
Description: Radiofrequency ablation for hepatic malignancies will be performed with manual registration registration. Except the imaging registration, all other procedures for RF ablation is same.
Study: NCT00649441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
Description: 20/25mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Accuretic™ Tablets 20 mg/25 mg
Description: 20/25mg, single dose fasting
Study: NCT03786198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity program
Description: Home-based walking intervention, wearing a wrist worn activity tracker, for 24 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Physical activity according to standard recommendations, wearing a wrist worn activity tracker (with no feedback about performed activity), for 24 weeks + standard adjuvant AI therapy
Study: NCT04157868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBNP
Description: rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour.
Study: NCT01344798

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV1-gamma-sarcoglycan vector injection
Description: single intramuscular injection into carpi radialis muscle under open procedure

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV1-gamma-sarcoglycan vector injection
Description: single intramuscular injection into carpi radialis muscle under open procedure
Study: NCT01131897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
Study: NCT02527395

Intervention type: OTHER
Group type: OTHER
Intervention: Brief thermal sensitization
Description: A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.

Intervention type: OTHER
Group type: OTHER
Intervention: Pain during 1 min. thermal stimulation
Description: A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.
Study: NCT02987816

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
Study: NCT03305536

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2 (Menaquinone 7) + Vitamin D3
Description: Vitamin K2 + Vitamin D3 arm will be compared with Vitamin D3 arm to slow of reverse the progression of the disease

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2 (Menaquinone 7) + Vitamin D3
Description: Vitamin K2 + Vitamin D3 arm will be compared with Vitamin D3 arm to slow of reverse the progression of the disease
Study: NCT02380105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Patients were informed of their condition and possible etiological factors contributing to the pathology. They were also educated about the postural rest position of the mandible and instructed to perform bilateral chewing and not overload the temporomandibular joint and masticatory muscles. Techniques to relieve pain and tension were taught to correct postural habits, food and sleep irregularities. The patients received written instructions for future reference, as a way of reinforcing the information provided during the initial consultation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interocclusal Appliances
Description: Patients were treated using interocclusal appliances
Study: NCT03072316

Intervention type: OTHER
Intervention: 3D surface imaging
Description: 3D photography

Intervention type: OTHER
Intervention: 3D surface imaging
Description: 3D photography

Intervention type: OTHER
Intervention: 3D surface imaging
Description: 3D photography

Intervention type: OTHER
Intervention: 3D surface imaging
Description: 3D photography

Intervention type: OTHER
Intervention: semi-structured interview
Description: qualitative analysis using semi structured interview

Intervention type: OTHER
Intervention: semi-structured interview
Description: qualitative analysis using semi structured interview

Intervention type: OTHER
Intervention: semi-structured interview
Description: qualitative analysis using semi structured interview
Study: NCT03831815

Intervention type: DRUG
Intervention: Cisatracurium
Description: Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist participating in the surgery. In group C, the patients in whom cisatracurium was given and the R group consisted of the patients in whom rocuronium was administered. It is emphasized that the choice of the neuromuscular blocker was made by the preference and experience of the anesthesiologist of the case and not by randomization or lottery of the patients.
Study: NCT00735670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine HCl
Description: Starting dose is 37.5 mg and ending dose is 150 mg at 13 weeks. From weeks 13 to 26 subjects no longer will receive the drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received a placebo instead of Venlafaxine HCl until week 13 as did the Venlafaxine group.
Study: NCT00799929

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: in vitro fertilization (IVF/ICSI)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: in vitro fertilization (IVF/ICSI)
Study: NCT03928353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Oral Tablet - Pre-Treatment
Description: Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo
Study: NCT02527395

Intervention type: OTHER
Group type: OTHER
Intervention: Heat pain detection threshold
Description: The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered. 4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements.
Study: NCT03072316

Intervention type: OTHER
Intervention: semi-structured interview
Description: qualitative analysis using semi structured interview

Intervention type: OTHER
Intervention: applanation tonometry
Description: measurement of breast compressibility

Intervention type: OTHER
Intervention: applanation tonometry
Description: measurement of breast compressibility

Intervention type: OTHER
Intervention: applanation tonometry
Description: measurement of breast compressibility

Intervention type: OTHER
Intervention: applanation tonometry
Description: measurement of breast compressibility
Study: NCT01109498

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Alipogene Tiparvovec (AMT-011), Human LPL [S447X]
Description: intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: oral, 2 g/day, day -3 till week 12

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Alipogene Tiparvovec (AMT-011), Human LPL [S447X]
Description: intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Alipogene Tiparvovec (AMT-011), Human LPL [S447X]
Description: intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections
Study: NCT03250494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulox capsule (60mg)
Description: each patient received Dulox capsule (60mg) orally with sips of water 2 hours preoperatively and 100 ml 0.9% sodium chloride solution (NS) intravenous infusion (IVI) over 15 min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined Dulox capsule (60 mg) orally and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI
Description: each patient received combined Dulox capsule (60 mg) orally with sips of water and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI over 15 min, 2 hours preoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone
Description: each patient received a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone 2 hours preoperatively.
Study: NCT04014855

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement
Description: in iron deficiency anemia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement
Description: in iron deficiency anemia
Study: NCT02302664

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRP Injection into Achilles tendon rupture gap
Description: PRP injection delivered into the tendon rupture gap Intervention - PRP Injection: The injection is the intervention. A blood sample is withdrawn from patient. Away from patient part of sample is spun down in centrifuge to produce 'Platelet Rich Plasma' (PRP). Patient returns to treatment area and their own PRP is then injected into tendon rupture gap. This is carried out by a surgeon or extended scope physiotherapist, generally in the outpatient clinic, after a local anaesthetic has been applied. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Remaining blood sample sent for analysis.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Imitation Injection into Achilles tendon rupture gap
Description: Imitation injection delivered into the tendon rupture gap Sham - Imitation Injection: The injection is the intervention. A blood sample is withdrawn from patient. Treatment is prepared. Patient returns to treatment area and a needle (no syringe) is inserted and held into tendon rupture gap to mimic injection (after local anaesthetic has been applied). No active ingredient given. Carried out by surgeon or extended scope physiotherapist, generally in the outpatient clinic. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Blood sample sent for analysis.
Study: NCT02351544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily headache diary

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily headache diary

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Migraine Disability Assessment Test (MIDAS)
Study: NCT03928353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Oral Tablet - Pre-Treatment
Description: Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
Description: Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo and Ticagrelor 180 mg 24 hours following PB2452 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Oral Tablet - Pre-Treatment
Description: Ticagrelor 180 mg BID for 5 doses prior to PB2452 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Oral Tablet - Pre-Treatment
Description: Ticagrelor 180 mg BID for 5 doses prior to PB2452 or Placebo
Study: NCT01109498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: oral, 3 mg/kg/day, day -3 till week 12
Study: NCT03928353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Oral Tablet - Pre-Treatment
Description: Ticagrelor 180 mg BID for 5 doses prior to PB2452 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB2452 Infusion
Description: 30 minute - 16 hour infusion
Study: NCT03965182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG
Description: 2 sachets of PEG will be used as the bowel prep regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG plus SPMC
Description: one sachet of PEG and one sachet will be administered as the bowel prep regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPMC
Description: 2 sachets will be administered as the bowel prep regimen.
Study: NCT03483454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise class
Description: Same as above.
Study: NCT04084249

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ctDNA-analysis
Description: Minimally-invasive blood-based analysis of circulating tumor DNA (ctDNA).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensified Follow-up Schedule
Description: PET/CT-scans every 3. month
Study: NCT01355549

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) therapy
Description: Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
Study: NCT02097394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combizym
Description: Combizym( 1 tablet, po, tid)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacteri
Description: Bifidobacteri (2 tablet, po, tid)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combizym + Bifidobacteri
Description: Combizym( 1 tablet, po, tid) + Bifidobacteri (2 tablet, po, tid)
Study: NCT03483454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise
Description: Same as above.
Study: NCT01111162

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1N1 vaccination
Description: Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles
Study: NCT03050957

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: menthol
Description: Alimentary bolus supplemented with menthol
Study: NCT02351544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Migraine Disability Assessment Test (MIDAS)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Migraine Work and Productivity Loss Questionnaire (MWPLQ)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Migraine Work and Productivity Loss Questionnaire (MWPLQ)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Migraine-Specific Quality of Life Questionnaire (MSQ)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Migraine-Specific Quality of Life Questionnaire (MSQ)
Study: NCT02593435

Intervention type: GENETIC
Intervention: NGS test
Description: To record the characteristic QC parameters and evaluate the detection performance of Next-Generation Sequencing (NGS), including coverage depth and sequence similarity, then be used to evaluate the quality of base recognition and alignment.~To know mutation characteristic spectrum of BRCA1/2.